Comparison of Plasma Input and Reference Tissue Models for Analysing [11C]flumazenil Studies

A single-tissue compartment model with plasma input is the established method for analysing [11C]flumazenil ([11C]FMZ) studies. However, arterial cannulation and measurement of metabolites are time-consuming. Therefore, a reference tissue approach is appealing, but this approach has not been fully validated for [11C]FMZ. Dynamic [11C]FMZ positron emission tomography scans with arterial blood sampling were performed in nine drug-free depressive patients and eight healthy subjects. Regions of interest were defined on co-registered magnetic resonance imaging scans and projected onto dynamic [11C]FMZ images. Using a Hill-type metabolite function, single (1T) and reversible two-tissue (2T) compartmental models were compared. Simplified reference tissue model (SRTM) and full reference tissue model (FRTM) were investigated using both pons and (centrum semiovale) white matter as reference tissue. The 2T model provided the best fit in 59% of cases. Two-tissue VT values were on average 1.6% higher than 1T VT values. Owing to the higher rejection rate of 2T fits (7.3%), the 1T model was selected as plasma input method of choice. SRTM was superior to FRTM, irrespective whether pons or white matter was used as reference tissue. BPND values obtained with SRTM correlated strongly with 1T VT (r = 0.998 and 0.995 for pons and white matter, respectively). Use of white matter as reference tissue resulted in 5.5% rejected fits, primarily in areas with intermediate receptor density. No fits were rejected using pons as reference tissue. Pons produced 23% higher BPND values than white matter. In conclusion, for most clinical studies, SRTM with pons as reference tissue can be used for quantifying [11C]FMZ binding.

[1]  D. R. Turton,et al.  An automated system based on solid phase extraction and HPLC for the routine determination in plasma of unchanged carbon-11 L-deprenyl Carbon-11 diprenorphine; carbon-11 flumazenil; Carbon-11 raclopride and Carbon-11 Scherring 23390 , 1993 .

[2]  B Walder,et al.  Similarity and Robustness of PET and SPECT Binding Parameters for Benzodiazepine Receptors , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  R. Myers,et al.  Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.

[4]  R. Koeppe,et al.  Parametric in vivo imaging of benzodiazepine receptor distribution in human brain , 1991, Annals of neurology.

[5]  François Mauguière,et al.  Seizure-related short-term plasticity of benzodiazepine receptors in partial epilepsy: a [11C]flumazenil-PET study. , 2005, Brain : a journal of neurology.

[6]  J. Baron,et al.  Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies , 1991, European Journal of Drug Metabolism and Pharmacokinetics.

[7]  C Crouzel,et al.  Quantification of Benzodiazepine Receptors in Human Brain Using PET, [11C]Flumazenil, and a Single-Experiment Protocol , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Karl J. Friston,et al.  Cortical grey matter and benzodiazepine receptors in malformations of cortical development. A voxel-based comparison of structural and functional imaging data. , 1997, Brain : a journal of neurology.

[9]  Js Duncan,et al.  QUANTIFICATION OF BENZODIAZEPINE RECEPTORS IN-VIVO USING C-11 FLUMAZENIL - APPLICATION OF THE STEADY-STATE PRINCIPLE , 1993 .

[10]  D E Kuhl,et al.  Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  Gerald Q. Maguire,et al.  Comparison and evaluation of retrospective intermodality brain image registration techniques. , 1997, Journal of computer assisted tomography.

[12]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  Giovanni Lucignani,et al.  GABAA receptor abnormalities in Prader–Willi syndrome assessed with positron emission tomography and [11C]flumazenil , 2004, NeuroImage.

[14]  D E Kuhl,et al.  Differentiation of Radioligand Delivery and Binding in the Brain: Validation of a Two-Compartment Model for [11C]Flumazenil , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  Michael S. Beauchamp,et al.  A parametric study of overt and covert shifts of spatial attention , 2000, NeuroImage.

[16]  D Comar,et al.  Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. , 1985, European journal of pharmacology.

[17]  Philippe Millet,et al.  Evaluation of the Reference Tissue Models for PET and SPECT Benzodiazepine Binding Parameters , 2002, NeuroImage.

[18]  H. Akaike A new look at the statistical model identification , 1974 .

[19]  T. Jones,et al.  Spectral Analysis of Dynamic PET Studies , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  J. S. Duncan,et al.  Benzodiazepine Receptor Quantification in vivo in Humans Using [11C]Flumazenil and PET: Application of the Steady-State Principle , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  Ronald Boellaard,et al.  Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET , 2001, European Journal of Nuclear Medicine.

[22]  H. Duvernoy The Human Brain , 1999, Springer Vienna.

[23]  Christer Halldin,et al.  Maps of receptor binding parameters in the human brain — a kinetic analysis of PET measurements , 2004, European Journal of Nuclear Medicine.

[24]  Roger N. Gunn,et al.  Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.

[25]  B. Gulyás,et al.  Regional increases in [11 C]flumazenil binding after epilepsy surgery , 1998, Acta neurologica Scandinavica.

[26]  J. Baron,et al.  Central benzodiazepine receptors in human brain: estimation of regional Bmax and KD values with positron emission tomography. , 1992, European journal of pharmacology.

[27]  Guy Marchal,et al.  Multimodality image registration by maximization of mutual information , 1997, IEEE Transactions on Medical Imaging.

[28]  Christer Halldin,et al.  Saturation analysis of specific 11C Ro 15‐1788 binding to the human neocortex using positron emission tomography , 1989 .

[29]  Z Rattner,et al.  Measurement of Benzodiazepine Receptor Number and Affinity in Humans Using Tracer Kinetic Modeling, Positron Emission Tomography, and [11C]Flumazenil , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  G. Sedvall,et al.  IN-VIVO DEMONSTRATION OF REDUCED BENZODIAZEPINE RECEPTOR BINDING IN HUMAN EPILEPTIC FOCI , 1988, The Lancet.

[31]  D J Brooks,et al.  Abnormalities of grey and white matter [11C]flumazenil binding in temporal lobe epilepsy with normal MRI. , 2002, Brain : a journal of neurology.

[32]  D J Brooks,et al.  Ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission , 2000, Neurology.

[33]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[34]  L. Barré,et al.  Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study , 1999, The European journal of neuroscience.

[35]  J. Baron,et al.  Regional Specific Binding of [11C]RO 15 1788 to Central Type Benzodiazepine Receptors in Human Brain: Quantitative Evaluation by PET , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  H. Duvernoy,et al.  The Human Brain: Surface, Three-Dimensional Sectional Anatomy with MRI, and Blood Supply , 1999 .

[37]  A. Anand,et al.  Cerebral benzodiazepine receptors in depressed patients measured with [123i]iomazenil SPECT , 2003, Biological Psychiatry.

[38]  P N Leigh,et al.  Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. , 2000, Brain : a journal of neurology.

[39]  A. Mans,et al.  Regional Distribution and Kinetics of Three Sites on the GABAA Receptor: Lack of Effect of Portacaval Shunting , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[41]  V J Cunningham,et al.  Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. , 1998, Archives of general psychiatry.

[42]  D J Brooks,et al.  Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.